Results of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older

Jorge Cortes, Hagop Kantarjian, Susan O'Brien, L. E. Robertson, Sherry Pierce, Moshe Talpaz

Research output: Contribution to journalArticle

Abstract

PURPOSE: To determine the response rate to interferon-alpha (IFN-α) in patients with chronic myelogenous leukemia (CML) aged 60 years and older. PATIENTS AND METHODS: Patients with CML aged 60 years and older included in all protocols with IFN-α therapy for early chronic phase CML at the M.D. Anderson Cancer Center were analyzed. They were treated with human leukocyte or recombinant human IFN-α 5x106 U/m2 daily alone or in combination with hydroxyurea or IFN gamma. The clinical characteristics of the patients were analyzed and their hematologic and cytogenetic responses to IFN-α and survival from the initiation of therapy were determined. Results were compared with those of younger patients treated in the same protocols. Treatment-related toxicity was also analyzed. RESULTS: Thirty-five of 274 (13%) patients included in trials of IFN-α-based regimens for CML were 60 years and older. Older patients had a higher percentage of bone marrow blasts (P = 0.04) and basophils (P = 0.09) than younger patients. Sixty-nine percent achieved a complete hematologic remission with IFN-α therapy, and 51% had a cytogenetic response, which was major in 26% and complete (Philadelphia chromosome-positive cells = 0%) in 20%. Their median survival was 64 months, and the estimated 5-year survival rate was 62%. These results were not different from those in younger patients. Twenty-two patients (63%) had at least grade 2 toxicity requiring dose adjustment. The most frequent side effects were neurotoxicity in 31% and chronic fatigue in 29%. CONCLUSIONS: Patients with CML 60 years of age and older respond well to IFN-α therapy, but experience more toxicity. This therapy should be considered for these patients if they are otherwise in good condition, with careful attention to IFN-α toxicity and its management.

Original languageEnglish (US)
Pages (from-to)452-455
Number of pages4
JournalAmerican Journal of Medicine
Volume100
Issue number4
DOIs
StatePublished - Apr 1996
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interferon-alpha
Therapeutics
Cytogenetics
Leukemia, Myeloid, Chronic Phase
Philadelphia Chromosome
Hydroxyurea
Survival
Basophils
Fatigue
Leukocytes
Survival Rate
Bone Marrow

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Results of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older. / Cortes, Jorge; Kantarjian, Hagop; O'Brien, Susan; Robertson, L. E.; Pierce, Sherry; Talpaz, Moshe.

In: American Journal of Medicine, Vol. 100, No. 4, 04.1996, p. 452-455.

Research output: Contribution to journalArticle

Cortes, Jorge ; Kantarjian, Hagop ; O'Brien, Susan ; Robertson, L. E. ; Pierce, Sherry ; Talpaz, Moshe. / Results of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older. In: American Journal of Medicine. 1996 ; Vol. 100, No. 4. pp. 452-455.
@article{88832d2fc41b40ff80701a7394aafb3a,
title = "Results of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older",
abstract = "PURPOSE: To determine the response rate to interferon-alpha (IFN-α) in patients with chronic myelogenous leukemia (CML) aged 60 years and older. PATIENTS AND METHODS: Patients with CML aged 60 years and older included in all protocols with IFN-α therapy for early chronic phase CML at the M.D. Anderson Cancer Center were analyzed. They were treated with human leukocyte or recombinant human IFN-α 5x106 U/m2 daily alone or in combination with hydroxyurea or IFN gamma. The clinical characteristics of the patients were analyzed and their hematologic and cytogenetic responses to IFN-α and survival from the initiation of therapy were determined. Results were compared with those of younger patients treated in the same protocols. Treatment-related toxicity was also analyzed. RESULTS: Thirty-five of 274 (13{\%}) patients included in trials of IFN-α-based regimens for CML were 60 years and older. Older patients had a higher percentage of bone marrow blasts (P = 0.04) and basophils (P = 0.09) than younger patients. Sixty-nine percent achieved a complete hematologic remission with IFN-α therapy, and 51{\%} had a cytogenetic response, which was major in 26{\%} and complete (Philadelphia chromosome-positive cells = 0{\%}) in 20{\%}. Their median survival was 64 months, and the estimated 5-year survival rate was 62{\%}. These results were not different from those in younger patients. Twenty-two patients (63{\%}) had at least grade 2 toxicity requiring dose adjustment. The most frequent side effects were neurotoxicity in 31{\%} and chronic fatigue in 29{\%}. CONCLUSIONS: Patients with CML 60 years of age and older respond well to IFN-α therapy, but experience more toxicity. This therapy should be considered for these patients if they are otherwise in good condition, with careful attention to IFN-α toxicity and its management.",
author = "Jorge Cortes and Hagop Kantarjian and Susan O'Brien and Robertson, {L. E.} and Sherry Pierce and Moshe Talpaz",
year = "1996",
month = "4",
doi = "10.1016/S0002-9343(97)89522-8",
language = "English (US)",
volume = "100",
pages = "452--455",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Results of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older

AU - Cortes, Jorge

AU - Kantarjian, Hagop

AU - O'Brien, Susan

AU - Robertson, L. E.

AU - Pierce, Sherry

AU - Talpaz, Moshe

PY - 1996/4

Y1 - 1996/4

N2 - PURPOSE: To determine the response rate to interferon-alpha (IFN-α) in patients with chronic myelogenous leukemia (CML) aged 60 years and older. PATIENTS AND METHODS: Patients with CML aged 60 years and older included in all protocols with IFN-α therapy for early chronic phase CML at the M.D. Anderson Cancer Center were analyzed. They were treated with human leukocyte or recombinant human IFN-α 5x106 U/m2 daily alone or in combination with hydroxyurea or IFN gamma. The clinical characteristics of the patients were analyzed and their hematologic and cytogenetic responses to IFN-α and survival from the initiation of therapy were determined. Results were compared with those of younger patients treated in the same protocols. Treatment-related toxicity was also analyzed. RESULTS: Thirty-five of 274 (13%) patients included in trials of IFN-α-based regimens for CML were 60 years and older. Older patients had a higher percentage of bone marrow blasts (P = 0.04) and basophils (P = 0.09) than younger patients. Sixty-nine percent achieved a complete hematologic remission with IFN-α therapy, and 51% had a cytogenetic response, which was major in 26% and complete (Philadelphia chromosome-positive cells = 0%) in 20%. Their median survival was 64 months, and the estimated 5-year survival rate was 62%. These results were not different from those in younger patients. Twenty-two patients (63%) had at least grade 2 toxicity requiring dose adjustment. The most frequent side effects were neurotoxicity in 31% and chronic fatigue in 29%. CONCLUSIONS: Patients with CML 60 years of age and older respond well to IFN-α therapy, but experience more toxicity. This therapy should be considered for these patients if they are otherwise in good condition, with careful attention to IFN-α toxicity and its management.

AB - PURPOSE: To determine the response rate to interferon-alpha (IFN-α) in patients with chronic myelogenous leukemia (CML) aged 60 years and older. PATIENTS AND METHODS: Patients with CML aged 60 years and older included in all protocols with IFN-α therapy for early chronic phase CML at the M.D. Anderson Cancer Center were analyzed. They were treated with human leukocyte or recombinant human IFN-α 5x106 U/m2 daily alone or in combination with hydroxyurea or IFN gamma. The clinical characteristics of the patients were analyzed and their hematologic and cytogenetic responses to IFN-α and survival from the initiation of therapy were determined. Results were compared with those of younger patients treated in the same protocols. Treatment-related toxicity was also analyzed. RESULTS: Thirty-five of 274 (13%) patients included in trials of IFN-α-based regimens for CML were 60 years and older. Older patients had a higher percentage of bone marrow blasts (P = 0.04) and basophils (P = 0.09) than younger patients. Sixty-nine percent achieved a complete hematologic remission with IFN-α therapy, and 51% had a cytogenetic response, which was major in 26% and complete (Philadelphia chromosome-positive cells = 0%) in 20%. Their median survival was 64 months, and the estimated 5-year survival rate was 62%. These results were not different from those in younger patients. Twenty-two patients (63%) had at least grade 2 toxicity requiring dose adjustment. The most frequent side effects were neurotoxicity in 31% and chronic fatigue in 29%. CONCLUSIONS: Patients with CML 60 years of age and older respond well to IFN-α therapy, but experience more toxicity. This therapy should be considered for these patients if they are otherwise in good condition, with careful attention to IFN-α toxicity and its management.

UR - http://www.scopus.com/inward/record.url?scp=0029664772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029664772&partnerID=8YFLogxK

U2 - 10.1016/S0002-9343(97)89522-8

DO - 10.1016/S0002-9343(97)89522-8

M3 - Article

C2 - 8610733

AN - SCOPUS:0029664772

VL - 100

SP - 452

EP - 455

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 4

ER -